Colforsin (Forskolin, HL 362)

For research use only. Not for use in humans.

目录号:S2449 别名: Coleonol, Colforsin 中文名称:佛司可林

Colforsin (Forskolin, HL 362) Chemical Structure

CAS No. 66575-29-9

Colforsin (Forskolin, HL 362, Coleonol, Colforsin)在各种各样细胞类型中,是一种普遍存在的真核细胞腺苷酸环化酶(AC)激活剂,在细胞生理学研究中,通常用来提高cAMP水平。Forskolin 还可激发 PXRFXR的活性而诱导自噬。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1144.16 现货
RMB 903.37 现货
RMB 3029.97 现货
RMB 4679.71 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Colforsin (Forskolin, HL 362)发表文献84篇:

产品安全说明书

cAMP抑制剂选择性比较

生物活性

产品描述 Colforsin (Forskolin, HL 362, Coleonol, Colforsin)在各种各样细胞类型中,是一种普遍存在的真核细胞腺苷酸环化酶(AC)激活剂,在细胞生理学研究中,通常用来提高cAMP水平。Forskolin 还可激发 PXRFXR的活性而诱导自噬。
靶点
Adenylyl cyclase (AC) [1]
(A wide variety of cell types)
体外研究

Forskolin可以使膜,细胞或组织制备液中cAMP含量上升。Forskolin 不仅可以活化AC 而且可以与某些其它蛋白相互作用,包括葡萄糖转运蛋白和离子通道。Forskolin能够促进9种不同独立AC形式的活化,虽然对AC9效率有点低,这可以用于提供一种鉴定和量化G蛋白 (Gs)–AC复合物高亲和性结合位点的方法。G蛋白偶联受体活化G蛋白有助于细胞中Forskolin刺激的cAMP 产生,因为 G蛋白-Forskolin对AC活性有增强作用[1]。Forskolin在不与细胞表面受体相互作用前提下刺激腺苷酸环化酶活性。在脂肪细胞中Forskolin's促进 cAMP产生进而可以抑制嗜碱性粒细胞和肥大细胞脱颗粒作用以及组胺释放,降低血压、眼内压,抑制血小板聚集,促进血管舒张,支气管扩张和甲状腺激素分泌,刺激脂肪分解。Forskolin 抑制血小板活化因子 (PAF)的结合, 这种抑制不依赖于cAMP形成可能是 Forskolin's 直接作用于 PAF或者通过干扰PAF与它的受体结合实现的。Forskolin似乎对多种膜转运蛋白也有效果并且可以抑制脂肪细胞,红细胞,血小板,和其他细胞中的葡萄糖运输。Forskolin也被用于治疗青光眼[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29  M{\nOGFxd3C2b4Ppd{BCe3OjeR?= Mn7QOFDDqM7:TR?= MXe0POKhcA>? NWPUOYtoTE2VTx?= NXrCSG1YcW6mdXPld{BkcGGwZ3XzJIlvKHSqZTDwbI9{eGixconsZZRqd25ic4TheJV{KG:oIGDQNmEhfGG{Z3X0dy=> M{jNWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUm3OFUyLz5{NEm5O|Q2OTxxYU6=
SW480 NWXre|VlSXCxcITvd4l{KEG|c3H5 NYj0eIxKPDEEoN88US=> NFXXW4U1QMLiaB?= M3TNNGROW09? MlTnbY5lfWOnczDjbIFv\2W|IHnuJJRp\SCyaH;zdIhwenmuYYTpc44he3SjdIXzJI9nKFCSMlGgeIFz\2W2cx?= NX;WXJU1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5PVc1PTFpPkK0PVk4PDVzPD;hQi=>
HT-29  M3nkc2Fxd3C2b4Ppd{BCe3OjeR?= NXnvPFdDPDEEoN88US=> NF6y[|E1QMLiaB?= NGnLfopFVVOR M2joOolv\HWlZYOgZY4h[WO2aY\heIlwdiCxZjDjZZNx[XOnIEOvOy=> MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl7N{S1NUc,OjR7OUe0OVE9N2F-
SW480 M3vJU2Fxd3C2b4Ppd{BCe3OjeR?= MnntOFDDqM7:TR?= NYezTFFtPDkEoHi= NFnPfJZFVVOR NHPTVodqdmS3Y3XzJIFvKGGldHn2ZZRqd25ib3[gZ4F{eGG|ZTCzM|c> M4C4SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUm3OFUyLz5{NEm5O|Q2OTxxYU6=
HT-29  MUjGeY5kfGmxbjDBd5NigQ>? NYDyR21XPDEEoN88US=> NIC1VHM4KGR? M3njV2ROW09? MWny[YR2[2W|IHPvcI9vd3OyaHXy[UBnd3KvYYTpc44h[2GyYXLpcIl1gcLi NEntRXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm5O|Q2OSd-MkS5PVc1PTF:L3G+
SW480 M3vRd2Z2dmO2aX;uJGF{e2G7 M1fmOlQxyqEQvF2= M2O1OVch\A>? M3O2NmROW09? M{e0bJJm\HWlZYOgZ49td26xc4Do[ZJmKG[xcn3heIlwdiClYYDhZoltcXS7wrC= NV:0UHBtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5PVc1PTFpPkK0PVk4PDVzPD;hQi=>
HT-29  M2LCdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWC0NoJCPDEEoN88US=> MWSwMVczKGh? MlHySG1UVw>? M4XJWolvcGmkaYTzJINmdGxiZ4Lve5RpKHSrbXWg[IVx\W6mZX70cJk> MkDqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OUe0OVEoRjJ2OUm3OFUyRC:jPh?=
SW480 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUm0NOKh|ryP M4T4V|AuPzJiaB?= MontSG1UVw>? NYnXco9QcW6qaXLpeJMh[2WubDDndo94fGhidHnt[UBl\XCnbnTlcpRtgQ>? M{nNWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUm3OFUyLz5{NEm5O|Q2OTxxYU6=
HT-29  Mnq3SpVv[3Srb36gRZN{[Xl? NWDrdmplPDEEoN88US=> NV23eIlPPDkEoHi= MXTEUXNQ NH\HSYxi[3SrdnH0[ZMhWFB{QR?= M1LiclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUm3OFUyLz5{NEm5O|Q2OTxxYU6=
SW480 MWLGeY5kfGmxbjDBd5NigQ>? NUPCW5ppPDEEoN88US=> NVzUU49WPDkEoHi= M2nFdGROW09? Mk\YZYN1cX[jdHXzJHBROkF? M1jNZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUm3OFUyLz5{NEm5O|Q2OTxxYU6=
C6 NFT3TVRHfW6ldHnvckBCe3OjeR?= NHjoVGUyOCEQvF5CpC=> M1frVVIxKG2rbh?= M{nTTolv[3KnYYPld{BkSU2SIHHjZ5VufWyjdHnvci=> NVuxNVV2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOlk1OTdpPkK1NFY6PDF5PD;hQi=>
Huh-7 MlewSpVv[3Srb36gRZN{[Xl? MV[wMVIxKM7:TR?= Ml\WNkBpyqB? NFXKZmtz\XO3bITzJIlvKGFiZH;z[U1l\XCnbnTlcpQhcW6lcnXhd4UhcW5iYz3NfYMh\XiycnXzd4lwdiCjdDD0bIUheHKxdHXpckBidmRibWLORUBt\X[nbIO= MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTFyOUizOEc,OjVzMEm4N|Q9N2F-
THP-1  MUDGeY5kfGmxbjDBd5NigQ>? MnzjNU8yOCEQvF2= M2nKPVLDqGh? NXq1VXdHTE2VT9Mg MoLPd5VxeHKnc4Pld{BOS1BvMTDwdo9lfWO2aX;uxsA> NIHGR3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG1OFg5Oid-MkWxOVQ5QDJ:L3G+
BeWo  MUjGeY5kfGmxbjDBd5NigQ>? NEXwRoIzOCEEtV2= MWi0PEBp NF;qPWZFVVORwrC= MlzlbY5lfWOnczDj[YxtKG[3c3nvci=> MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF6NES3O{c,OjVzOES0O|c9N2F-
ventricular cardiomyocytes  MUPGeY5kfGmxbjDBd5NigQ>? MWCwMlAyNTFyIN88US=> Mki3[ZZwc2W|IHHuJIlvd3S{b4DpZ{Bz\XOyb37z[UAyOjEEsUG1KUBi[m:4ZTDiZZNidCC5aYToJIFvKEWFNUFCpI9nKDJwMjFCuW0> M4rBXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkCzNVE{Lz5{NUKwN|EyOzxxYU6=
ventricular cardiomyocytes  M4qz[mZ2dmO2aX;uJGF{e2G7 NWH0WpJ6OC5yMT2xNEDPxE1? M2T0T4lv[3KnYYPld{Ah[0GPUDDhZ4N2dXWuYYTpc44> NV24RZFzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyNFMyOTNpPkK1NlA{OTF|PD;hQi=>
MIN6  MWfGeY5kfGmxbjDBd5NigQ>? MVOxNEDPxE4EoB?= M3\mR|MhcA>? NETqUWNqdmO{ZXHz[ZMhTDNibWLORUBmgHC{ZYPzbY9v M3rlN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkSxNVI1Lz5{NUK0NVEzPDxxYU6=
L6 MYrGeY5kfGmxbjDBd5NigQ>? Mlj5OFAhyrWP MkjBNlQhcA>? NIX4XJBqdmirYnn0d{BFVUhzLXnu[JVk\WRiQXv0JIFkfGm4YYTpc44> NYPXepdIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOFc2PTBpPkK1NlQ4PTVyPD;hQi=>
HEK‐CFTR MXPGeY5kfGmxbjDBd5NigQ>? NITmcm4z6oDVNUFCpO69VQ>? MWiwMVEzKG2rbh?= M2PNOmROW00EoB?= MoHmbY5lfWOnczDhJIRwe2YkgKDk[ZBmdmSnboSgbY9lcWSnIHXm[ox2gMLi NVi5VVRjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOlMzODdpPkK1NlY{OjB5PD;hQi=>
SK-N-SH NI\JPJBE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NFHzSFkyOCEQvF5CpC=> NFvmN2M1QCCq NVvDUoVu\W6qYX7j[ZMhW0tvTj3TTEBv\XW{b3LsZZN1d22jIHPlcIwhfmmjYnnsbZR6 NX\PWGtFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOlYxPjNpPkK1NlY3ODZ|PD;hQi=>
SK-N-AS  NH\rO5dHfW6ldHnvckBCe3OjeR?= NHznUXEyOCEQvF5CpC=> MYmxNE8{OC94MDDtbY4> NGPvXZhqdmO{ZXHz[ZMhdGW4ZXzzJI9nKHBvzsKtZ4F1\W6rbjCod4VzPjd3KTDhcoQhcW6mdXPld{Bi[2O3bYXsZZRqd25ib3[gdE3Pui2lYYTlcolvKCi|ZYK2O|UqKGmwIDjw[ZJqMW63Y3zlZZIhemWpaX;udy=> Mn[2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{Nk[wOlMoRjJ3Mk[2NFY{RC:jPh?=
SK-N-AS  MnflSpVv[3Srb36gRZN{[Xl? MornNVAh|ryPwrC= MmDSN|AhdWmw MVvpcoR2[2W|IIDoc5NxcG:{eXzheIlwdiCxZjFOtk1k[XSnbnnuJEh{\XJ4N{WpMEBxNUeVS{ROtkApe2W{OTmgZY5lKGOxbnPvcYl1[W62IHjp[4hmeiCuZY\lcJMhd2ZiYXP0bZZmNCC3boDoc5NxcG:{eXzheIVlNCEQsj3jZZRmdmmw M3LZeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mk[2NFY{Lz5{NUK2OlA3OzxxYU6=
SK-N-AS  NVTYbW9RTnWwY4Tpc44hSXO|YYm= MmOzNVAh|ryPwrC= NYftUFM1OjRiaB?= MorUbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJIN6[2yrbjDENS=> NVLXZ2tvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOlYxPjNpPkK1NlY3ODZ|PD;hQi=>
SK-N-AS  Ml3HSpVv[3Srb36gRZN{[Xl? NEfEPI4yOCEQvF5CpC=> M4XoNlI1KGh? MVfpcoNz\WG|ZYOgeIhmKGODTWCgcIV3\Wy|wrC= NI\MN|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK2OlA3Oyd-MkWyOlYxPjN:L3G+
SK-N-AS  MWrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MWCxNEDPxE4EoB?= NIjhRngzPC92ODDo Mk\C[Y5p[W6lZYOgeIlu\S2mZYDlcoRmdnSueTDj[YxtfWyjcjD2bYFjcWyrdIpCpC=> NInZTI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK2OlA3Oyd-MkWyOlYxPjN:L3G+
granulosa cells NVfzS3BrTnWwY4Tpc44hSXO|YYm= NUPudnJpOTBizszN M1W0VVI1KGh? M4fwVolv[3KnYYPld{B1cGVibHX2[Yx{KG:oIGLHV|IheHKxbX;0[ZIh[WO2aY\peJk> MmDuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV|M{mxNFUoRjJ3M{O5NVA2RC:jPh?=
granulosa cells MXPGeY5kfGmxbjDBd5NigQ>? NYP5[ZV2OTBizszN NHfKS|EzPCCq NYTRU5A5cW6lcnXhd4V{KHSqZTDpcpRmdnOrdImgc4YhTE6DL4Dyc5RmcW5iY3;tdIxmgA>? M1O2S|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{O5NVA2Lz5{NUOzPVExPTxxYU6=
granulosa cells NUf2SGJOTnWwY4Tpc44hSXO|YYm= NIP5XFEyOCEQvF2= NULVV2x1OTJxMkSgbC=> MVvpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iC{ZYDvdpRmeiCjY4Tpeol1gSCob4KgeIhmKGyxbnfld5Qh\nKjZ33lcpQhMOLKkki1OE8sOTiUR2OyMmxWSyl? NXO2UHh2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzN|kyODVpPkK1N|M6OTB3PD;hQi=>
granulosa cells NEPaPVFHfW6ldHnvckBCe3OjeR?= M4LUZlExKM7:TR?= MlewNVIwOjRiaB?= MXvpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\sLiUlfTNuKhdVKQQR?= NYnIfXY1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzN|kyODVpPkK1N|M6OTB3PD;hQi=>
BeWo  MXrGeY5kfGmxbjDBd5NigQ>? NUCxSVR5OjEEoNM1US=> MVW0POKhcMLi M{SwfGROW00EoB?= NIjxW2Nld3ewcnXneYxifGW|IITo[UBt\X[nbDDv[kBIS01vMR?= MmD1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV|NkKyOlAoRjJ3M{[yNlYxRC:jPh?=
BeWo  NIqxUpJHfW6ldHnvckBCe3OjeR?= Ml\ONlDDqML3TR?= NXXH[W05PDkEoHlCpC=> M1vnS2ROW00EoB?= M4nKWoRwf26{ZXf1cIF1\XNidHjlJIxmfmWuIH;mJHROTU2IMU[= NVOzfGNFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzOlIzPjBpPkK1N|YzOjZyPD;hQi=>
BeWo  MUfGeY5kfGmxbjDBd5NigQ>? NET5V48zOMLiwsXN NWOwSJI1PDkEoHlCpC=> MVXEUXNQyqB? NEKyU|lqdmO{ZXHz[ZMhfGinIHLleIEucEOJIILlcIVie2V? M{jKdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{[yNlYxLz5{NUO2NlI3ODxxYU6=
EM1  M{fxcGZ2dmO2aX;uJGF{e2G7 MmC2NVXjiIsQvF2= MWW0PEBp NHH6S2xz\WS3Y3XzJJRp\SCneIDy[ZN{cW:wIH;mxsBNUUcEoH;yxsBRXEeVMtMgbY7DqEODTGKtJI9zyqCHUFHDNk1{cWynbnPl[EBGVTFiY3XscJPDqA>? M4nqcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{e4OlYyLz5{NUO3PFY3OTxxYU6=
Primary bovine chondrocytes NFrDfFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M32yeFXPxE1? NIfOcGY1QCCq NFn0UY1z\X[ncoPld{B1cGViaX7obYJqfG:{eTDl[oZm[3Rib3[gZ4Vt\WOxeHniJI9vKHC{b3zp[oVz[XSrb36gbY4h\3Kxd4ToJJBt[XSnIHPoc45lem:leYTldy=> NYjqb4h{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NFYxOTZpPkK1OFA3ODF4PD;hQi=>
RBMECs NUnwU|JuTnWwY4Tpc44hSXO|YYm= NE\QcXc2yqEQvF2= MmTZNUBp NVjyNW9X[myxY3vzJJRp\SCjY4TpckBkgXSxc3vlcIV1d25icnXhdpJidmenbXXueEB{\WWwIIfpeIghTU2DUD3JTUB1emWjdH3lcpTDqA>? NYHtcIlwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NVY3PTFpPkK1OFE3PjVzPD;hQi=>
RBMECs NIq3TWZHfW6ldHnvckBCe3OjeR?= Mn3iOeKh|ryP NHGyZ2QyKGh? MoS2Zoxw[2u|IITo[UBGVUGSLVnJMYlv\HWlZXSgZ4hidmenIHnuJG1NSyCyaH;zdIhwenmuYYTpc44> MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTRzNk[1NUc,OjV2MU[2OVE9N2F-
RBMECs MYDGeY5kfGmxbjDBd5NigQ>? NVzyXYFQPcLizszN NWGxdnY3OSCq MnTBdoV3\XK|ZYOgeIhmKGOqYX7n[ZMhcW5iWl:tNUBlcXO2cnnieZRqd25ic3XlckB4cXSqIFXNRXAuUUlidILlZZRu\W62 Mlf6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MU[2OVEoRjJ3NEG2OlUyRC:jPh?=
RBMECs NITUSYtHfW6ldHnvckBCe3OjeR?= NH74NWI2yqEQvF2= Ml\BNUBp M4WwXYlvcGmkaYTzJJRp\SCmZXPy[YF{\WRib3[gZY1wfW62IH;mJHpQNTFiaX6gUWZ{KGmwZIXj[YQh[nliRV3BVE1KUQ>? NITKdGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSxOlY2OSd-MkW0NVY3PTF:L3G+
RBMECs NVzKT|FWTnWwY4Tpc44hSXO|YYm= Mo[1OeKh|ryP NXXuN4trOSCq NYnaWFIxeHKndnXueJMhfGinIHnuZ5Jm[XOnIHnuJGhTWCCobIX4JIFkem:|czD0bIUhSlSEIHnu[JVk\WRiYomgJGVOSVBvSVm= M2rWdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEG2OlUyLz5{NUSxOlY2OTxxYU6=
RBMECs NYLPSFRpTnWwY4Tpc44hSXO|YYm= MYS1xsDPxE1? M4DCUFEhcA>? Ml[1dJJmfmWwdIOgeIhmKEWPQWCtTWkucW6mdXPl[EBVTUWUII\hcJVmKGSnY4LlZZNm M2fGRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEG2OlUyLz5{NUSxOlY2OTxxYU6=
RBMECs MoTNSpVv[3Srb36gRZN{[Xl? NYi5bZRmPcLizszN MlL4NUBp NGrObFdjdG:la4OgeIhmKGGldHn2ZZRqd25ib3[gVohwSS:UT1PLJIlv\HWlZXSgZpkhTU2DUD3JTS=> MmK4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MU[2OVEoRjJ3NEG2OlUyRC:jPh?=
RBMECs NUnDepJITnWwY4Tpc44hSXO|YYm= Mk\sNE4xPS9yLkWvOUDPxE1? M{fEVVAvOjViaB?= M4LE[olv[3KnYYPld{BkSU2SIHPvcoNmdnS{YYTpc44> M{jXUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEG2OlUyLz5{NUSxOlY2OTxxYU6=
ThGCs  NWrj[HdRTnWwY4Tpc44hSXO|YYm= MmLlNVDjiIsQvF2= NFnVV|A{KGh? NIP5coRqdmirYnn0d{B1cGViZX\m[YN1KG:oIFiyU|Ihd25iRVTONkBuWk6D NYPJdY13RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0N|MxOjdpPkK1OFM{ODJ5PD;hQi=>
ThGCs  NEjFRmNHfW6ldHnvckBCe3OjeR?= M17wRVEx6oDMzszN MlPTOQKBkmh? MmjobY5kemWjc3XzJGNwS2x{LXnu[JVk\WRiRVTONuKh\2WwZTDlfJBz\XO|aX;u NHS5d5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSzN|AzPyd-MkW0N|MxOjd:L3G+
ThGCs  NVXSfWtETnWwY4Tpc44hSXO|YYm= NXnBcnNlOTEkgJtOwG0> MYC05qCLcA>? NWD1eXZv[XWpbXXueJMhUEmIMVGgcIV3\Wy|IIToZZQhf2W{ZTDzeIlufWyjdHXkJIJ6KEOxQ3yy NYjSWW9KRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0N|MxOjdpPkK1OFM{ODJ5PD;hQi=>
LNCaP  NG\1VJNHfW6ldHnvckBCe3OjeR?= NUjBfoc{OTEEoN88US=> M3vTS|EzKGkEoB?= NWLXN|JUTE2VTx?= NFTrU|VqdmS3Y3XzJIEh\HKjbXH0bYMhcW6lcnXhd4Uhd2ZiQ2LFRlEh[WO2aY\peJk> MnPTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NEiwPVkoRjJ3NUS4NFk6RC:jPh?=
BeWo NXj3[pVETnWwY4Tpc44hSXO|YYm= M4fEUVIxyqEEtV2= MV[0POKhcA>? NEDKb2tFVVOR NVzYSXd{cW6lcnXhd4V{KHSqZTDh[Ihme2mxbjDv[kBVUFBvMTDtc45w[3m2ZYO= M4nGbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NU[2O|QxLz5{NUW2Olc1ODxxYU6=
BeWo MW\GeY5kfGmxbjDBd5NigQ>? NGnscZMzOMLiwsXN Ml3TOFjDqGh? NXOzOJFiTE2VTx?= NH\yZpVqdmO{ZXHz[ZMhfGinIHTp[oZmemWwdHnheIlwdiCxZjDC[XdwKGOnbHzz MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV4Nke0NEc,OjV3Nk[3OFA9N2F-
OCI-Ly18  MmrzSpVv[3Srb36gRZN{[Xl? MojqOFDDqM7:TR?= M3PJW|HDqGkEoB?= MmL4SG1UVw>? MXLpcoR2[2W|IITo[UBqdmO{ZX3lcpQhd2ZiY1HNVEBkd26lZX70doF1cW:wcx?= NHztN209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW3OlIzOCd-MkW1O|YzOjB:L3G+
OCI-Ly1  MmHiSpVv[3Srb36gRZN{[Xl? NGCwRXE1OMLizszN M2XmTFHDqGkEoB?= NYqyNZBKTE2VTx?= MWfpcoR2[2W|IITo[UBqdmO{ZX3lcpQhd2ZiY1HNVEBkd26lZX70doF1cW:wcx?= M1\FRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUe2NlIxLz5{NUW3OlIzODxxYU6=
3T3-L1 MULGeY5kfGmxbjDBd5NigQ>? MVKyMlUwPSEQvF2= M3XSSVI1KGkEoB?= MVPzbYdvcW[rY3HueIx6KGSnY4LlZZNmeyCDVFfMJJBzd3SnaX6g[ZhxemW|c3nvckBifCCjbHyg[I9{\XNidHXzeIVl NEHsOWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW5NFU6Pyd-MkW1PVA2QTd:L3G+
HEK293  MnrISpVv[3Srb36gRZN{[Xl? M3HuflXjiIoEtV2= MV:zNEBucW5? MX;pcoNz\WG|ZYOgZ2FOWCCuZY\lcJM> M13ONVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUmxPVA5Lz5{NUW5NVkxQDxxYU6=
hADSCs Mn;FSpVv[3Srb36gRZN{[Xl? M4PQcFXjiIoEtV2= MonWN|AhdWmw M1viU4lv[3KnYYPld{BkSU2SIHzleoVtew>? NF7GbVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW5NVkxQCd-MkW1PVE6ODh:L3G+
SH-SY5Y  NGnWdHdHfW6ldHnvckBCe3OjeR?= MmPFNVDDqM7:TR?= NIPmN3cyyqCqwrC= MkfobY5kemWjc3XzJGFISzFibWLORUBt\X[nbB?= NH\1RoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW5O|Q{Oyd-MkW1PVc1OzN:L3G+
SH-SY5Y  MYjGeY5kfGmxbjDBd5NigQ>? NFW0[pQyOMLizszN MXexxsBpyqB? NXzxU|BPcW6lcnXhd4V{KEyXQzDhZ5Rqfmm2eR?= M3v5flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUm3OFM{Lz5{NUW5O|Q{OzxxYU6=
UACC-647  NVLURYlUTnWwY4Tpc44hSXO|YYm= MVSxNOKh|ryP NUTaOmJGOTVibXnu MWPEUXNQ NFfPfFRqdmO{ZXHz[ZMh\UWIMjDwbI9{eGixconsZZRqd25ibHX2[Yx{yqB? MormQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5MEOwNlUoRjJ3N{CzNFI2RC:jPh?=
UACC-647  NFX3SIVHfW6ldHnvckBCe3OjeR?= NVPOVmlDOTEEoN88US=> MlnCNVUhdWmw NVPUc5RDTE2VTx?= MmnBbY5pcWKrdIOgSXJMKHCqb4PwbI9zgWyjdHnvci=> MlfGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5MEOwNlUoRjJ3N{CzNFI2RC:jPh?=
UACC-647  NX;2VYN2TnWwY4Tpc44hSXO|YYm= NHHVR2xFVVOR NFe1eo5t\WGmczD0c{BiKHKrc3WgbY4h[0GPUDDs[ZZmdHNiKFXDOVDDqD4EoEKwMlM6yqEQvF2p M4XuOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{CzNFI2Lz5{NUewN|AzPTxxYU6=
SC MXvGeY5kfGmxbjDBd5NigQ>? MlnUNE42KM7:TR?= M2L3XlczKGh? Mnz4bY5kemWjc3XzJIJwfGhiS4LvfE0zOCCjbnSgU|Eh\XiycnXzd4lwdiCrbjDhfI9vNXKnbHH0[YQhW0O|IHL1eEBwdmy7IFvyc5guOjEEoB?= NYH0c4tZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NFU5PzRpPkK1O|A2QDd2PD;hQi=>
SC Ml;xSpVv[3Srb36gRZN{[Xl? M3;sRlAvPSEQvF2= NXj1TIh3OjRiaB?= MVztbY1q[2u|IITo[UBm\m[nY4Sgc4Yh[0GPUDDhcoFtd2e|IH;uJG8yKGGwZDDNRnAh\XiycnXzd4lwdg>? NITy[Ig9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUewOVg4PCd-MkW3NFU5PzR:L3G+
oocytes M3zqZ2Z2dmO2aX;uJGF{e2G7 NXHWNJVwPSEQvF2= M3vQflI1KGh? NWHJN2ZE[XS2ZX71ZZRmeyC{aD3pcpN2dGmwIHHjeIlwdiCxbjDvc4N6fGViR2\CSEB{cWewaX\pZ4FvfGy7wrC= MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTdyN{i1OEc,OjV5MEe4OVQ9N2F-
BeWo NFTnfolHfW6ldHnvckBCe3OjeR?= MV:xNQKBks7:TdMg NFPpUWg4OiCq M4izdWROW09? MVrt[YRq[XSnczDC[XdwKGOnbHyg[Iln\mW{ZX70bYF1cW:w M2[2fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{GzOFI2Lz5{NUexN|QzPTxxYU6=
GH3 NUGydllSTnWwY4Tpc44hSXO|YYm= NYq4OGtVOcLizszN M3LBU|YucA>? M4jsdolv\HWlZYOgVHJNKGGwZDDCcYFtOSxiYoX0JI5wfCCFbH;jb{whdVKQQTDlfJBz\XO|aX;u Mlq4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5MkewNVgoRjJ3N{K3NFE5RC:jPh?=
GH3 NID1SYZHfW6ldHnvckBCe3OjeR?= Mkf1NeKh|ryP M3O0PVYucA>? NH\yb29ifHSnboXheIV{KHSqZTDjc5Jz\WyjdHnvckBj\XS5ZXXuJHBTVCCjbnSgRo1idDFiZYjwdoV{e2mxbh?= NWrPW4R7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NlcxOThpPkK1O|I4ODF6PD;hQi=>
PC12 Mo\CSpVv[3Srb36gRZN{[Xl? NUXYZWZoOjYEoN88US=> NIH3dHI1QCCq NVjOVIFI[WO2aY\heIV{KGODTWC= M3;KNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{[5N|A2Lz5{NUe2PVMxPTxxYU6=
BAECs NH\kdlhHfW6ldHnvckBCe3OjeR?= MUKyOUDPxE1? MV:yOEBp MlLq[Y5p[W6lZYOgeIhmKGGldHn2ZZRqd25ib3[gVHBCWs7zIHL5JFUh|ryPIILld5ZmemG2cn;sMEBVPEiVLDDvdkA1NVCDUB?= M4SwbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{m4PFI3Lz5{NUe5PFgzPjxxYU6=
GLUTag  Mom5SpVv[3Srb36gRZN{[Xl? MV6xNQKBkcL3TR?= NXHEU3V2PCCq NIfxbHJqdmO{ZXHz[ZMhfGinIIDDVmVDKGyndnXsd{B4cXSqIITo[UBKSk2[ MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh|Mk[zNUc,OjV6M{K2N|E9N2F-
GLUTag  NHGyXVdHfW6ldHnvckBCe3OjeR?= MkDvNVDjiIoEtV2= NUPOR3ZqOC9{L{SgbC=> NVTlblgxe3SrbYXsZZRmeyCJTGCtNUB{\WO{ZYTpc44h[2:2cnXheIVlKHerdHigTWJOYA>? MorsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6M{K2N|EoRjJ3OEOyOlMyRC:jPh?=
PBMC NFXnW4JHfW6ldHnvckBCe3OjeR?= NV3mPY9RPTEEoN88US=> M4[xb|I1yqCqwrC= NYnZfIpYcW6qaXLpeJMhfGinIHnuZ5Jm[XOnZDDz[YNz\XSrb36gc4YhXE6IIHnu[JVk\WRiYomgeIhmKESSRR?= NGnwV|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi2OlA4QSd-MkW4OlYxPzl:L3G+
H295R  NFn4PVhHfW6ldHnvckBCe3OjeR?= MXyxNOKh|ryP NHz1ZnU1QMLiaB?= NXzSdnAycW6lcnXhd4V{KHO2ZYLvbYQhdWW2YXLvcIl1\XNiaX6geIhmKGGwZILv[4VvNCCvaX7ldoFtdy1iYX7kJIdtfWOxY3;yeIlkd2mmIIDheIh4[Xm| MlLZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6Nkm1OVYoRjJ3OE[5OVU3RC:jPh?=
3T3-L1 preadipocytes Mn;ySpVv[3Srb36gRZN{[Xl? M2DOeVExKM7:TdMg NEPTUHQyOiCq NG\UTllqdmS3Y3XzJGNTTUJicHjvd5Bpd3K7bHH0bY9vKGGwZDDDM2VDWM7{IHX4dJJme3Orb36= M1;zTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUK4NFU5Lz5{NUmyPFA2QDxxYU6=
PCCL3 M37RTGZ2dmO2aX;uJGF{e2G7 NGTaR3YyOCEEtV2= MoCzNlQhcA>? NFm1WIhmdmijbnPld{BFfU:6MjDwdo9ud3SncjD0doFve2O{aYD0bY9vKGGldHn2bZR6yqEkgJu= MnvFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NkC5OVYoRjJ3OU[wPVU3RC:jPh?=
SCG MXvGeY5kfGmxbjDBd5NigQ>? NYXlVGs{OTByIN88UeKh NF3ISo9FVVOR M3HwVpJm\HWlZYOgeIhmKGW6Y3n0ZYJqdGm2eTDv[kBUS0dibnX1do9vew>? NVrxU5ZrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OlIyOzJpPkK1PVYzOTN{PD;hQi=>
HEK-293 NFHLT5NHfW6ldHnvckBCe3OjeR?= MX[zOUDPxE4EoB?= NUPJT5RYTE2VTx?= NV7XWWRKcW6mdXPld{BiKGOxboPwbYN2d3W|IPMAoIlv[WO2aY\heIlwduLCnTDv[kB1cGViS4[yMlEh[3W{cnXueC=> NFz2PY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm2NlE{Oid-MkW5OlIyOzJ:L3G+
SCG NUPpPZhjTnWwY4Tpc44hSXO|YYm= MX[yNEDPxE4EoB?= MWPEUXNQ Mn;sdoV3\XK|aXLsfUB{fXCycnXzd4V{KEmNVjD3bZRpKGFiSVO1NEBw\iB{ND60JO69VQ>? MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl4MkGzNkc,OjV7NkKxN|I9N2F-
PC-3 MWjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NV;XRo1IPDBiwsXN NGW2NXEzPC92OD:3NkBp MVHEUXNQ NHHuXJZl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgeIlu\SCmZYDlcoRmdnSueR?= M1H2W|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEKzPFM3Lz5{NkCyN|g{PjxxYU6=
PC-3 NFLkWGRHfW6ldHnvckBCe3OjeR?= NX7DRWF4PDBiwsXN NGP4ZW8zKGh? NYn5eG9iTE2VTx?= NWLacFJ3dGWjZIOgeI8hWFB{QTDhZ5RqfmG2aX;u NITQXmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCyN|g{Pid-Mk[wNlM5OzZ:L3G+
SH-SY5Y NVXWcHpYTnWwY4Tpc44hSXO|YYm= MoTlN|Ah|ryP MW[zNEBucW5? NIfEV2tFVVOR MlPOd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNidHjlJIFkfGm4YYTpc44hd2ZiUFvB NYfle4c5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNlUyOzdpPkK2NFI2OTN5PD;hQi=>
EndoC-βH1 NV23bYx4TnWwY4Tpc44hSXO|YYm= NHf1fYk2yqEQvF2= NIr6[IIyKGh? NFThXJJt\WGmczD0c{BiKHO2cn;u[{BkSU2SIHnuZ5Jm[XOn NUfadpVTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNlg2PjJpPkK2NFI5PTZ{PD;hQi=>
EndoC-βH1 NIrVNoxHfW6ldHnvckBCe3OjeR?= NYO5VGNUPcLizszN NHnzR2gyKGh? NXjuT3ZFeG:2ZX70bYF1\XNiZ3z1Z49{\S2rbnT1Z4VlKGmwc4XsbY4he2WlcnX0bY9vKGmwIITo[UBxemW|ZX7j[UBw\iCpbIXjc5Nm M2LReFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEK4OVYzLz5{NkCyPFU3OjxxYU6=
RBMECs MU\GeY5kfGmxbjDBd5NigQ>? MX21xsDPxE1? MW[xJIg> MUTpcohq[mm2czDFUWFRNUmLLXnu[JVk\WRiaX7hZ5RqfmG2aX;uJI9nKFKjcEJCpC=> MmnwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNES2OlMoRjJ4MES0OlY{RC:jPh?=
AML-12  NILoV49HfW6ldHnvckBCe3OjeR?= M1PZXlIxKM7:TR?= NVnh[m1FOyCq M4HqTolv\HWlZYOgeIhmKGSncHjvd5Bpd3K7bHH0bY9vKG:oIFPSWGMzyqB? MnmyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNEi5PFUoRjJ4MES4PVg2RC:jPh?=
AML-12  NULRdZpPTnWwY4Tpc44hSXO|YYm= M33xZlIxKM7:TR?= MlrRN{Bp MXT1dE1z\We3bHH0[ZPDqFCpY{HhMOKhWGWyY3usJIFv\MLiR{\wZ:KhdVKQQTDs[ZZmdHN? MmLxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNEi5PFUoRjJ4MES4PVg2RC:jPh?=
AML-12  NF;4ZotHfW6ldHnvckBCe3OjeR?= NYHO[XdoOjBizszN M4rjOFEuQCCq NEL4fotqdmO{ZXHz[ZMh\2y3Y3;z[UBxem:mdXP0bY9v M3jkSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MES4PVg2Lz5{NkC0PFk5PTxxYU6=
AML-12  M{PRfGZ2dmO2aX;uJGF{e2G7 NH\Jb5QzOCEQvF2= NVPmO5h2OyCq M163PJVxemWpdXzheIV{KHSqZTDwbI9{eGixconsZZRqd25ibHX2[Yx{KGG2IGTodk01OTFiYX7kJHNmei12OUO= MlfmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNEi5PFUoRjJ4MES4PVg2RC:jPh?=
Caco-2  MnzDSpVv[3Srb36gRZN{[Xl? NIHWWWcxNjFxMT:xNEDPxE1? MUGyOEBp MUDpcoNz\WG|ZYOgUXJROiCycn;0[YlvKGyndnXs NIXheow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC0PVExOid-Mk[wOFkyODJ:L3G+
Caco-2  Mni4SpVv[3Srb36gRZN{[Xl? NHfuNo8xNjFxMT:xNEDPxE1? NYHU[JBvOjEEoH3pci=> MWfpcoR2[2W|IHGg[I9{\S2mZYDlcoRmdnRiaX7jdoVie2ViaX6gbY51emGlZXzseYxieiClQV3QJIxmfmWucx?= MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB2OUGwNkc,OjZyNEmxNFI9N2F-
bovine oocytes MXTGeY5kfGmxbjDBd5NigQ>? NXLFXZVyOTBywrFOwG0> NXvKWI9WOTMEoHi= M{TZXolvcGmkaYTzJJRp\SCnZn\lZ5Qhd2ZiTmDQRUBidmRxb4KgUnBRSyC2bzDzeIlufWyjdHWgdoV{fW2ydHnvckBw\iCvZXnvd4l{ M3\2SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEWxOlEyLz5{NkC1NVYyOTxxYU6=
BeWo  Mnn1SpVv[3Srb36gRZN{[Xl? MYGyOgKBkc7:TR?= MUeyOE81QC95MjDo NUDjWoNidGWjZIOgeI8h[W5iaX7jdoVie2ViaX6geIhmKGW6cILld5Nqd25ib3[gc5Rp\XJiZoXzbY9vKG2jcnvldpM> MoOyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNUO1OFkoRjJ4MEWzOVQ6RC:jPh?=
Spinal cords  MonWSpVv[3Srb36gRZN{[Xl? MnPhNeKh|ryP M2C1O|MxKG2rbh?= NVvOT3VEe3SrbYXsZZRmeyClQV3QJIxmfmWucx?= NIP1eZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGyOlkzPid-Mk[xNlY6OjZ:L3G+
MDCK  MkTlSpVv[3Srb36gRZN{[Xl? M3:ySFExKML3TR?= NIrp[5gzPCCq NIDhOGdFVVOR M4fE[IlvcGmkaYTzJJRp\SCrbnPy[YF{\WRiZYjwdoV{e2mxbjDv[kBHViClYYXz[YQh[nliVFfGMe6zOQ>? MmPLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{MEKzOVIoRjJ4MkCyN|UzRC:jPh?=
MDCK  NWnJZlE4TnWwY4Tpc44hSXO|YYm= MUixNEDDvU1? NYDFflNjOjRiaB?= NEDDSppFVVOR NVzrZ2xvfXC{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiVFfGMe6zOSCjbnSgR3RITsLi NUXYfHZDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yNFI{PTJpPkK2NlAzOzV{PD;hQi=>
RPMI 8226 MmTjR4VtdCCYaXHibYxqfHliQYPzZZk> NYXXdnpHOC1zMECg{txO MofRO|LjiImq Ml7pbY5lfWOnczDj[YxtKGSnYYToJIRwe2ViZHXw[Y5l\W62bIm= MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjNyNk[yOEc,OjZ|ME[2NlQ9N2F-
H929 M4HSOGNmdGxiVnnhZoltcXS7IFHzd4F6 NVv5WWZ4OC1zMECg{txO Mm\JO|LjiImq MXjpcoR2[2W|IHPlcIwh\GWjdHig[I9{\SCmZYDlcoRmdnSueR?= Mnz6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ|ME[2NlQoRjJ4M{C2OlI1RC:jPh?=
U266 M3z2[GNmdGxiVnnhZoltcXS7IFHzd4F6 MlHhNE0yODBizszN M13uS|cz6oDLaB?= NYLJPVRWcW6mdXPld{Bk\WyuIHTlZZRpKGSxc3Wg[IVx\W6mZX70cJk> MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjNyNk[yOEc,OjZ|ME[2NlQ9N2F-
OPM-2 NGPBPJJE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MkfaNE0yODBizszN NUjsW3Q1PzMkgJno MWPpcoR2[2W|IHPlcIwh\GWjdHig[I9{\SCmZYDlcoRmdnSueR?= M2i0O|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{C2OlI1Lz5{NkOwOlYzPDxxYU6=
INA-6 NX7RfZVvS2WubDDWbYFjcWyrdImgRZN{[Xl? MoTUNE0yODBizszN NX\4dJE{PzMkgJno MUXpcoR2[2W|IHPlcIwh\GWjdHig[I9{\SCmZYDlcoRmdnSueR?= NVHPTWxxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zNFY3OjRpPkK2N|A3PjJ2PD;hQi=>
RBMECs  MX;GeY5kfGmxbjDBd5NigQ>? MVu1xsDPxE1? MYSxxsBp NGn5SoljdG:la4OgeIhmKFKjY{GgbY5i[3SrdnH0bY9vKGmwZIXj[YQh[nliRV3BVE1KUQ>? NWLWcFdrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zOVgxOzlpPkK2N|U5ODN7PD;hQi=>
Mo-DCs NWfiTnBvTnWwY4Tpc44hSXO|YYm= MomyOVAh|ryP MXiyOQKBkWh? M4PGd5Bzd22xdHXzJGlNNTJ|IIDyc4R2[3Srb36gbY4hfGinIIP1dIVzdmG2YX70JI9nKHq7bX;zZY4he3SrbYXsZZRm\CCPbz3ER5PDqA>? M{jqVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NEGyPVQ5Lz5{NkSxNlk1QDxxYU6=
HEK293 MnzRSpVv[3Srb36gRZN{[Xl? NFXpc|MyOCEQvF2= M3f1S|YhcA>? MmnRbY5kemWjc3XzJJBpd3OyaH;yfYxifGmxbjDv[kBwfmW{ZYjwdoV{e2WmIFvMTGw{KGG2IGO0N|M> NFPxNmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkSzOVQ6QCd-Mk[0N|U1QTh:L3G+
ASK MYnGeY5kfGmxbjDhd5NigQ>? MV6xJIhz NHLSV249[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OES5OlQyLz5{OES5OlQyRC:jPh?=
Vero E6 MVrBcpRqfmm{YXygZZN{[Xl? NWTtTINXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe2OlM2OzlpPkG3OlY{PTN7PD;hQi=>
epithelial cells NXLzSWJoTnWwY4Tpc44h[XO|YYm= NFvGfIUyKHWP MV[0MEA3NCCjbnSgPEBl[Xm| MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTl4Nke4PUc,OTl7Nk[3PFk9N2F-
HepG2 (DPX-2) M2m0TmZ2dmO2aX;uJIF{e2G7 MnXzNlQhcHK| MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODl4NkC0N{c,OjB7Nk[wOFM9N2F-
HepG2 NVLDVXNzTnWwY4Tpc44h[XO|YYm= NYDaUnE6OjRiaILz MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODl4NkC0N{c,OjB7Nk[wOFM9N2F-
HepG2 (DPX-2) MnzoSpVv[3Srb36gZZN{[Xl? NEX6W3IzPCCqcoO= MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODl4NkC0N{c,OjB7Nk[wOFM9N2F-
HEK293T NWLnc3p7TnWwY4Tpc44h[XO|YYm= MVWxNEB2VQ>? NXHrT5J1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzPFc{OjVpPkK0N|g4OzJ3PD;hQi=>
HEK293 M2rGO2Z2dmO2aX;uJIF{e2G7 NWHBTWhnOTBidV2= NIDrN|YyPiCqcoO= M4jtUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NEO1OVEzLz5{NkSzOVUyOjxxYU6=
MCF7 NVvFbnhMS3m2b4TvfIlkcXS7IHHzd4F6 NX30XJhVPDhiaILz MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh|OE[5Nkc,Ojh6M{i2PVI9N2F-
HEK293 NYPEeGJTTnWwY4Tpc44h[XO|YYm= M3O5XVMxKG2rboO= Ml3tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByME[xO|YoRjNyMEC2NVc3RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
cleaved caspase-3 / caspase-3; 

PubMed: 30863177     


Toledo, NK-92, RL, and Farage cells were treated with 30 μM of forskolin for 48 hours, then the cells were harvested for Western blotting to assess the expression of total or cleaved caspase-3

cleaved caspase-9 / caspase-9 ; 

PubMed: 30863177     


Toledo, NK-92, RL, and Farage cells were treated with 30 μM of forskolin for 48 hours, then the cells were harvested for Western blotting to assess the expression of total or cleaved caspase-9.

β-catenin; 

PubMed: 30863177     


(A, B) The protein expression of cytoplasmic and nuclear β-catenin in Toledo and NK-92 cells in the presence of 0, 10, 20, or 40 μM forskolin was detected by Western blotting.

c-myc / Cyclin D1; 

PubMed: 30863177     


(C, D) Western blotting analysis of the total protein expression of c-myc and cyclin D1 influenced by 0, 10, 20, or 40 μM of forskolin in Toledo and NK-92 cells (n=3, *P<0.05, forskolin group vs control group).

pS6K1 / S6K1 / pCREB / CREB; 

PubMed: 31112131     


Forskolin inhibits mTORC1 in multiple cell lines. PC3, LNcap/AR, H1299, H1944, MDA-MB-231, MEF, HAP1, COS7, HeLa, MIA Paca-2, and PANC-1 were treated with or without 10 μM forskolin for 1 h and mTORC1 activity, CREB phosphorylation, and loading controls were analyzed.

p-JNK / JNK / P-p38 / p38; 

PubMed: 20070884     


L929 cells were pretreated with forskolin (10 μM) for various times as indicated, followed by stimulation with or without 10 ng/ml TNF-α for 15 min.

30863177 31112131 20070884
Immunofluorescence
5hmC; 

PubMed: 29239726     


Schwann cells were treated with forskolin (10 μM) for 3 hr followed by washout. 5hmC induction was detected at of 0, 3, and 24 hr time points following treatment. Cells continuously treated with forskolin (5, 10 μM) for 24 hr showed comparable 5hmC levels. Scale bar = 20 μm. 

Fe(II); 

PubMed: 29239726     


AMP (100 mM) treatment for 4 hr did not induce labile Fe(II) while AC activators (forskolin (100 mM), bicarbonate (50 mM)) and PDE inhibitors (caffeine (100 mM), IBMX (100 mM)) increased labile Fe(II) detected by Trx-Puro probes.

CYP17A1 / CYP21A2; 

PubMed: 25334044     


H295R cells were treated with 8-Br-cAMP or forskolin for 48 h under growth conditions, and fixed with 4% paraformaldehyde. (A) Immunostaining for CYP17A1. Red staining shows the anti-CYP17A1 antibody and blue staining shows DAPI (cell nuclei). (B) Immunostaining for CYP21A2. Red staining shows the anti-CYP21A2 antibody and blue staining shows DAPI (cell nuclei). Scale bars represent 100 µm.

29239726 25334044
Growth inhibition assay
Cell viability; 

PubMed: 30863177     


(C) MTT assay was conducted to test the cell growth after Toledo cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 1, 2, 3, 4, 5, or 6 days. (D) Toledo cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 48 hours, then MTT assay was used to evaluate the IC50 of forskolin. (F) MTT assay was conducted to test the cell growth after NK-92 cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 1, 2, 3, 4, 5, or 6 days. (G) NK-92 cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 48 hours, then MTT assay was used to evaluate the IC50of forskolin. 

30863177

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

溶解度 (25°C)

体外 DMSO 82 mg/mL (199.75 mM)
Water Insoluble
Ethanol ''37 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 410.5
化学式

C22H34O7

CAS号 66575-29-9
储存条件 粉状
溶于溶剂
别名 Coleonol, Colforsin

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04254705 Not yet recruiting Procedure: Rectal Biopsy Cystic Fibrosis Universitaire Ziekenhuizen Leuven|Vertex Pharmaceuticals Incorporated|KU Leuven|University of Lisbon March 1 2020 Not Applicable
NCT02807415 Completed Drug: Lumacaftor plus Ivacaftor Cystic Fibrosis Hannover Medical School|Heidelberg University|University of Giessen June 1 2016 --
NCT02586883 Completed Other: bronchial ddp test Idiopathic Dilation of the Bronchi Assistance Publique - Hôpitaux de Paris March 29 2016 Not Applicable
NCT03652090 Completed Procedure: cell sampling Cystic Fibrosis Institut National de la Santé Et de la Recherche Médicale France|ABCF2 September 1 2010 --

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

cAMP Signaling Pathway Map

Tags: 购买Colforsin (Forskolin, HL 362) | Colforsin (Forskolin, HL 362)供应商 | 采购Colforsin (Forskolin, HL 362) | Colforsin (Forskolin, HL 362)价格 | Colforsin (Forskolin, HL 362)生产 | 订购Colforsin (Forskolin, HL 362) | Colforsin (Forskolin, HL 362)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID